For healthcare professionals only

This promotional website has been developed, organised and funded by Boehringer Ingelheim.​

Prescribing information for Great Britain, Northern Ireland and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.

Focus on: Ramadan

Prior to Ramadan, it is important to undertake medication reviews of your adult patients with type 2 diabetes who wish to fast during this time

Did you know?

In a study of 11,000 Muslims with type 2 diabetes, 79% fasted during Ramadan despite being exempted due to their medical condition 1

Leaflet to share with your patients

Alia Gilani

Supporting your patients during Ramadan

  • This leaflet, designed for patients, outlines the key considerations a person with diabetes should be aware of when planning to fast during Ramadan
  • Includes a link to a patient video discussing considerations prior to Ramadan fasting

Developed by Alia Gilani,
Senior Diabetes Clinical Pharmacist,
Primary Care Sheffield, Sheffield

Alia is a part-time Senior Diabetes Clinical Pharmacist for Primary Care Sheffield, whose interests lie in ethnic inequalities and diabetes. She helped to establish and run a bilingual medication review service in NHS Glasgow in 2002 and received local and national awards for this work. She has chaired the NHS Glasgow Diabetes Ethnicity and Inequalities Group in the past. 

Alia has been running outreach clinics for South Asian people with diabetes for over a decade and was a member of the Diabetes Working Group for the South Asian Health Foundation (SAHF) for 13 years and had the role of Regional Lead and Chief Executive Officer for 2 years. She was the first pharmacist on the Primary Care Diabetes Society (PCDS) and a committee member for 7 years.

Healthcare professional resources

Professor Wasim Hanif

Click here to view video

The risks of fasting during Ramadan in adults with type 2 diabetes

  • Potential risks for adults with type 2 diabetes wishing to fast during Ramadan
  • Available screening options for this population

Supporting your patients during Ramadan

  • This 2-page fact sheet summarises the steps to take when reviewing adults with type 2 diabetes who wish to observe Ramadan

Reference: Salti I et al. Diabetes Care 2004;27:2306–11

Sarah Jarvis
Webinar Series Chair

Watch the most recent webinar

Initiated and funded by
Boehringer Ingelheim
PC-GB-110175 V2 | December 2024
Prescribing information for Great Britain, Northern Ireland and the Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].

PC-GB-106628 V6 | December 2024

PC-GB-110742 | December 2024

This website is for healthcare professionals in the United Kingdom and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in the United Kingdom or the Republic of Ireland by clicking below.

Quick questionnaire

Prescribing information for the United Kingdom and the Republic of Ireland 

You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.